Dorzolamide Cyclodextrin Nanoparticle Eye Drops Lower Intraocular Pressure Over 24 Hours

Abstract

Purpose: : To test dorzolamide cyclodextrin nanoparticle eye drops applied once a day for intraocular pressure control.

Methods: : Self aggregating cyclodextrin nanoparticle eye drops (DorzNP) containing 3% dorzolamide were formulated. The effect of the DorzNP eye drops once a day (QD) was compared to Trusopt® (Merck Inc, USA) applied 3 times a day (TID) in a prospective randomized double masked crossover trial. Seven healthy volunteers with intraocular pressure (IOP) over 18 mmHg have been recruited so far. IOP was measured with an Icare tonometer pro (Icare Finland Oy, Helsinki, Finland) and each patient underwent full eye examination.

Conclusions: : Preliminary results suggest that once a day dorzolamide nanoparticle eye drops have a similiar effect on intraocular pressure as Trusopt® applied 3 times a day. The trial will be continued and a larger number of patients will supply a more definitive conclusion. The dorzolamide nanoparticle eye drops are well tolerated and significantly reduce intraocular pressure.

Clinical Trial: : https://eudract.ema.europa.eu 2010-02381​1-32

Keywords: intraocular pressure • carbonic anhydrase • drug toxicity/drug effects